We're a group of industrial veterans and growing talents.
Founder and CEO
Gen Li, Ph.D., MBA, is an industry leader in, and regular presenter on productivity improvement in Clinical Development with more than 20 years’ experience. Before founding PhESi in 2006, Gen was Head of Productivity for Pfizer Worldwide Clinical Development. He also delivered the first implementation of productivity measurement for Clinical Development while serving as the Director of Performance Management in Pharmacia. His contributions to CMR International’s database for pharmaceutical R&D performance were from the client side (Pfizer/Pharmacia), assuring key parameters were collected during the clinical trial process were representative of the critical path for delivery. Gen earlier led the creation of the first computer automated resource management system at Bristol-Myers Squibb.
Gen received the prestigious Upjohn Award from Pfizer/Pharmacia. Gen earned his Ph.D. in Biochemistry from Beijing University, and an MBA from Johnson Graduate School of Management, Cornell University.
Head of Client Services
Jonathan Peachey is an industry expert leading and delivering business and IT transformation across pharmaceutical R&D. He has over 25 years’ experience with specific expertise in Clinical Development, Clinical Operations and Outsourcing. Jonathan’s demonstrated capabilities span strategy, business and IT management, performance improvement and solution design through to implementation.
Prior to joining PhESi Jonathan was a Board Director at Kinapse and IBM's European Pharma R&D consulting lead. Jonathan worked as a Clinical Program Leader at GSK, BMS and Pfizer.
Jonathan holds a first class honours degree and an Advanced Strategy diploma from Said Business School, Oxford University.
Chief Information Officer
Guoqiang Wu is a highly respected IT professional with broad experience in software development, system engineering and solution architecture. He strives to combine state of art technology and innovative thinking to meet business challenges. Prior to joining PhESi, he led the design and implementation of business-critical solutions in McKesson Corporation, as well as Microsoft Corporation. His work has earned him the Engineering Excellence award during his 12 years with Microsoft, and the Excellence in Technology award from McKesson.
Guoqiang holds a MS degree in Computer Science from North Carolina State University and a MS degree in Chemistry from Beijing University.
Andrew Della-Coletta is a pharmaceutical and life science expert who has successfully implemented transformational business and IT solutions across the pharma and biotech industry. Andrew has extensive expertise gained from 30 years of experience in Clinical Development, Clinical Operations, information design, compliance and governance of change initiatives to combine with leadership and analytical skills to successfully design and implement critical solutions for both process and technology.
Prior to working with PhESi, Andrew managed many Clinical Development and eClinical projects and programs for Pfizer/Pharmacia and AstraZeneca before joining IBM Business Consulting in Life Sciences. Andrew has a MS degree in Biological Sciences from Purdue University.
Vanda De Cian
Vanda De Cian, MD is has 30+ years of experience in all aspects of drug development in the pharmaceutical industry where she held staff and management positions at incremental level of seniority.
Before launching her own consulting business, Dr. De Cian was Vice President Corporate Drug Development at Chiesi Group, where she revamped R&D processes and delivered improved operational performance and increased R&D productivity. Prior to that, Dr. De Cian was Head of Clinical Operations for Europe and Asia, Pharmacia, managing operations in 40 countries. Among other achievements, Dr. De Cian successfully led a corporate project aimed at redesigning the drug development process to achieve dramatic improvements in the contemporary measurements of performance.
Dr. De Cian received her medical degree from Università degli Studi di Milano.
Albert Wai-Kit Chan
Albert Wai-Kit Chan, Ph.D., J.D., is the Managing Partner of the Law Offices of Albert Wai-Kit Chan, PLLC. He handles all areas of intellectual property law (including technology transfer, patents, trademarks, copyrights, business transactions and trade secrets), with a specialty in biotechnology patents. Dr. Chan works extensively with both U.S. and international companies.
He taught as an adjunct professor of law at The City University of New York School of Law. Dr. Chan is active in several legal organizations including United States-China Intellectual Property Institute, Inc. (a New York based Not-For-Profit Corporation) where he is founder and director.
Dr. Chan received his J.D. degree from Columbia University School of Law in New York. He was awarded his Ph.D. in virology at Baylor College of Medicine in Houston, Texas.
Nigel has over 20 years’ expertise and leadership using data and analytics to optimise pharmaceutical R&D operations, including Strategic Planning, Portfolio Analysis/Management, Project Valuation, Dynamic Pipeline Modelling, Enterprise Project/Resource Management and Performance Management.
In addition to consulting with Deloitte, PwC, IMS, IBM and PA, he has performed multi-year interim positions within global pharma companies, plus recently led the enhancement of GlobalData’s pharma market intelligence databases, including clinical trials and investigators.
Nigel holds a Master of Engineering degree from the University of Nottingham.